Robert L. Redner

4.2k total citations
63 papers, 2.6k citations indexed

About

Robert L. Redner is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Robert L. Redner has authored 63 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hematology, 38 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Robert L. Redner's work include Acute Myeloid Leukemia Research (38 papers), Retinoids in leukemia and cellular processes (27 papers) and Histone Deacetylase Inhibitors Research (12 papers). Robert L. Redner is often cited by papers focused on Acute Myeloid Leukemia Research (38 papers), Retinoids in leukemia and cellular processes (27 papers) and Histone Deacetylase Inhibitors Research (12 papers). Robert L. Redner collaborates with scholars based in United States, Netherlands and France. Robert L. Redner's co-authors include Johnson M. Liu, Jianxiang Wang, Arthur W. Nienhuis, J T Holt, Taizo Hoshino, Sachiko Kajigaya, Yogen Saunthararajah, Daniel E. Johnson, Kathleen Dorritie and M. Cooke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Robert L. Redner

60 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert L. Redner United States 21 1.8k 1.2k 478 306 266 63 2.6k
Roberta Riccioni Italy 23 1.4k 0.8× 812 0.7× 523 1.1× 461 1.5× 166 0.6× 45 2.1k
Hirotaka Matsui Japan 28 1.4k 0.8× 780 0.7× 368 0.8× 270 0.9× 161 0.6× 116 2.3k
Utz Krug Germany 25 1.1k 0.6× 980 0.8× 432 0.9× 233 0.8× 114 0.4× 82 2.0k
SR Frankel United States 12 2.1k 1.2× 1.6k 1.3× 341 0.7× 259 0.8× 476 1.8× 19 2.8k
Gerrard Teoh United States 25 1.6k 0.9× 1.2k 1.0× 1.1k 2.3× 437 1.4× 155 0.6× 56 2.5k
Edgar Jost Germany 23 1.0k 0.6× 551 0.5× 392 0.8× 314 1.0× 117 0.4× 100 1.8k
Pascale Cornillet‐Lefèbvre France 23 793 0.5× 931 0.8× 313 0.7× 305 1.0× 131 0.5× 49 2.0k
G Schwab United States 16 988 0.6× 566 0.5× 1.0k 2.1× 390 1.3× 446 1.7× 23 2.3k
Dario Ferrero Italy 25 872 0.5× 1.0k 0.9× 472 1.0× 338 1.1× 148 0.6× 92 2.0k
Zheng Ge China 27 1.5k 0.9× 450 0.4× 346 0.7× 183 0.6× 131 0.5× 134 2.4k

Countries citing papers authored by Robert L. Redner

Since Specialization
Citations

This map shows the geographic impact of Robert L. Redner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Redner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Redner more than expected).

Fields of papers citing papers by Robert L. Redner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Redner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Redner. The network helps show where Robert L. Redner may publish in the future.

Co-authorship network of co-authors of Robert L. Redner

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Redner. A scholar is included among the top collaborators of Robert L. Redner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Redner. Robert L. Redner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Redner, Robert L., Jan H. Beumer, Patricia Kropf, et al.. (2018). A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia & lymphoma. 59(11). 2595–2601. 10 indexed citations
2.
Bixby, Dale L., Carlos E. Vigil, Joseph G. Jurcic, et al.. (2017). Pharmacodynamic and pharmacokinetic evaluation of SY-1425 (tamibarotene) in biomarker-selected acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Annals of Oncology. 28. v367–v367. 1 indexed citations
3.
Agha, Mounzer, Anastasios Raptis, Jing‐Zhou Hou, et al.. (2016). Leukapheresis in patients newly diagnosed with acute myeloid leukemia. Transfusion and Apheresis Science. 55(2). 216–220. 20 indexed citations
4.
Abécassis, Irina, et al.. (2016). The leukemic oncoprotein NPM1-RARA inhibits TP53 activity. Leukemia & lymphoma. 57(8). 1933–1937. 2 indexed citations
5.
Hou, Jing‐Zhou, et al.. (2015). Outcomes of acute myeloid leukemia with t(15;17) not associated with acute promyelocytic leukemia. Leukemia & lymphoma. 56(11). 3236–3239. 2 indexed citations
6.
Johnson, Daniel E. & Robert L. Redner. (2015). An ATRActive future for differentiation therapy in AML. Blood Reviews. 29(4). 263–268. 45 indexed citations
7.
Hood, Brian L., et al.. (2014). Extrinsic Apoptosis Is Impeded by Direct Binding of the APL Fusion Protein NPM-RAR to TRADD. Molecular Cancer Research. 12(9). 1283–1291. 10 indexed citations
8.
Dorritie, Kathleen, Robert L. Redner, & Daniel E. Johnson. (2014). STAT transcription factors in normal and cancer stem cells. Advances in Biological Regulation. 56. 30–44. 29 indexed citations
9.
McLaughlin, Brian, Annie Im, Anastasios Raptis, et al.. (2012). Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. International Journal of Hematology. 96(6). 743–747. 9 indexed citations
10.
Foon, Kenneth A., Robert L. Redner, Anastasios Raptis, et al.. (2011). Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. Leukemia Research. 35(7). 885–888. 13 indexed citations
11.
Gore, Steven D., Ivana Gojo, Mikkael A. Sekeres, et al.. (2010). Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia. Journal of Clinical Oncology. 28(6). 1047–1053. 69 indexed citations
12.
Egorin, Merrill J., Susan M. Christner, Leonard J. Appleman, et al.. (2009). Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. British Journal of Clinical Pharmacology. 68(3). 370–374. 51 indexed citations
13.
Egorin, Merrill J., et al.. (2008). Effect of antacid on imatinib absorption. Cancer Chemotherapy and Pharmacology. 63(3). 525–528. 41 indexed citations
14.
George, James N., Susan D. Mathias, Ronald S. Go, et al.. (2008). Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trials. British Journal of Haematology. 144(3). 409–415. 113 indexed citations
15.
Rego, Eduardo Magalhães, Davide Ruggero, Carla Tribioli, et al.. (2005). Leukemia with distinct phenotypes in transgenic mice expressing PML/RARα, PLZF/RARα or NPM/RARα. Oncogene. 25(13). 1974–1979. 44 indexed citations
16.
Wang, Jianxiang, Yogen Saunthararajah, Robert L. Redner, & Johnson M. Liu. (1999). Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.. PubMed. 59(12). 2766–9. 169 indexed citations
17.
Gerszten, Peter C., William C. Welch, Michael Spearman, Charles A. Jungreis, & Robert L. Redner. (1997). Isolated deep cerebral venous thrombosis treated by direct endovascular thrombolysis. Surgical Neurology. 48(3). 261–266. 41 indexed citations
18.
Weinberger, Miriam, Inas Elattar, Seth M. Steinberg, et al.. (1992). Patterns of Infection in Patients with Aplastic Anemia and the Emergence of Aspergillus As a Major Cause of Death. Medicine. 71(1). 24–43. 95 indexed citations
19.
McManaway, Mary E., Bruce Shiramizu, Kishor Bhatia, et al.. (1990). Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. The Lancet. 335(8693). 808–811. 115 indexed citations
20.
Holt, Jeffrey T., Robert L. Redner, & Arthur W. Nienhuis. (1988). An oligomer Complementary to c- myc mRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation. Molecular and Cellular Biology. 8(2). 963–973. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberta Riccioni Breakdown of academic impact, for papers by Hirotaka Matsui Breakdown of academic impact, for papers by Utz Krug Breakdown of academic impact, for papers by SR Frankel Breakdown of academic impact, for papers by Gerrard Teoh Breakdown of academic impact, for papers by Edgar Jost Breakdown of academic impact, for papers by Pascale Cornillet‐Lefèbvre Breakdown of academic impact, for papers by G Schwab Breakdown of academic impact, for papers by Dario Ferrero Breakdown of academic impact, for papers by Zheng Ge
Rankless by CCL
2026